Skip to main content
. 2021 Jul 20;12:4404. doi: 10.1038/s41467-021-24601-y

Fig. 8. Re-expression of MYST1 inhibits TGFβ-dependent fibroblast activation and prevents experimental fibrosis.

Fig. 8

a, b Overexpression of MYST1 in cultured human dermal fibroblasts: a Expression of αSMA (n = 4 biological replicates per group) and formation of stress fibers (n = 5 biological replicates per group). Representative images and quantification. Horizontal scale bar, 100 µm. b mRNA levels of COL1A1 analyzed by qRT-PCR (n = 5 biological replicates per group), total collagen as analyzed by hydroxyproline assays (n = 4 biological replicates per group) and type I collagen protein as analyzed by western blot (n = 5 biological replicates per group). c–e Adenoviral overexpression of MYST1 in murine models. c TβRIact-induced skin fibrosis: Representative trichrome stainings for, dermal thickening, myofibroblast counts and hydroxyproline content (n = 4 biological replicates per group). d Bleomycin-induced pulmonary fibrosis: Representative Trichrome stainings, fibrotic area, myofibroblast counts, Ashcroft scores and hydroxyproline content (n = 4 biological replicates for the group AdMyst1 treated with TGFβ and n = 3 for other groups). e Bleomycin-induced dermal fibrosis: Representative trichrome stainings shown, dermal thickening, myofibroblast counts and hydroxyproline content (n = 4 biological replicates for bleomycin treated groups and n = 3 for saline treated groups). Horizontal scale bars, 100 µm. All data are presented as median ± IQR. p-values were determined by ANOVA one-way with Tukey’s multiple comparison post hoc test and are indicated in the figure. See source data for more detailed information. rel.: relative, Ad: adenovirus, conc.: concentration, int.: intensity, TβRIact: constitutively active TGFβ receptor type I, Bleo: bleomycin.